Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production

Blood

Volumn 108, Issue 1, 2006, Pages 390-399

  Zeiser, Robert ^b   Nguyen, Vu H ^b   Beilhack, Andreas ^b   Buess, Martin ^b   Schulz, Stephan ^b   Baker, Jeanette ^b   Contag, Christopher H ^b   Negrin, Robert S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CYCLOSPORIN A; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BONE MARROW TRANSPLANTATION; CD4+ CD25+ T LYMPHOCYTE; CELL FUNCTION; CELL PROLIFERATION; CYTOKINE PRODUCTION; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY COMPLEX; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 33745633856     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-01-0329     Document Type: Article

References (48)

1. + regulatory T cells preserve graft-vs-tumor activity while inhibiting graft-vs-host disease after bone marrow transplantation. Nat Med. 2003;9:1144-1149.
2. Jones S, Murphy GF, Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant. 2003;9:243-256.
3. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003;112:1688-1696.
4. Curiel T, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.
5. Malek T, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Immunol Rev. 2004;4:665-670.
6. + regulatory T-cell function. J Exp Med. 2002;196:851-857.
7. + T cell suppressor function. J Immunol. 2004;172:6519-6523.
8. + T cell suppressor function. Eur J Immunol. 2004;34:366-376.
9. + suppressor T cells: more questions than answers. Nat Rev Immunol. 2002;2:389-400.
10. + regulatory T cells in the absence of IL-2 signaling. Nat Immunol. 2005;6:1152-1159.
11. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A functional role for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005;6:1142-1151.
12. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201:723-735.
13. Bram R, Hung DT, Martin PK, Schreiber SL, Crabtree GR. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol. 1993;13:4760-4769.
14. Wiederrecht G, Sabers CJ, Brunn GJ, Martin MM, Dumont FJ, Abraham RT. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog Cell Cycle Res. 1996;1:53-71.
15. Allison A, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant. 1996;10:77-82.
16. Cao Y, Wagers AJ, Beilhack A, et al. Shifting foci of hematopoiesis during reconstitution from single stem cells. Proc Natl Acad Sci U S A. 2004;101:221-226.
17. Lyons A, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods. 1994;171:131-137.
18. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T cell subsets. Blood. 2005;106:1113-1122.
19. Lerner K, Kao GF, Storb R, Buckner CD, Clift RA, Thomas ED. Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc. 1974;6:367-371.
20. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficiency of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003;101:640-648.
21. Taylor P, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99:3493-3499.
22. Blazar B, Taylor PA, Panoskaltsis-Mortari A, Sehgal S, Vallera DA. In vivo inhibition of cytokine responsiveness and graft-versus-host disease mortality by rapamycin leads to a clinical-pathological syndrome discrete from that observed with cyclosporin A. Blood. 1996;87:4001-4009.
23. Contassot E, Robinet E, Angonin R, et al. Differential effects of cyclosporin A on the alloreactivity of fresh and ex vivo-expanded T lymphocytes. Bone Marrow Transplant. 1998;22:1097-1102.
24. Townsend R, Gilbert MJ, Korngold R. Combination therapy with a CD4-CDR3 peptide analog and cyclosporin A to prevent graft-vs-host disease in a MHC-haploidentical bone marrow transplantation model. Clin Immunol Immunopathol. 1998;86:115-119.
25. Blazar B, Taylor PA, Snover DC, Sehgal SN, Vallera DA. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. J Immunol. 1993;151:5726-5741.
26. Shapira M, Hirshfeld E, Weiss L, et al. Mycophenolate mofetil does not suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model. Cancer Immunol Immunother. 2005;54:383-388.
27. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128-135.
28. Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol. 2001;167:1945-1953.
29. + T cells in the periphery. Transplantation. 2004;77:183-189.
30. + regulatory T cells. Blood. 2005;105:4743-4748.
31. + regulatory T cells. Blood. 2006;107:1018-1023.
32. Baan C, van der Mast BJ, Klepper M, et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation. 2005;80:110-117.
33. Malek T, Yu A, Vincek V, et al. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity. 2002;17:167-170.
34. Hackstein H, Taner T, Logar AJ, Thomson AW. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood. 2002;100:1084-1087.
35. Mehling A, Grabbe M, Voskort T, Schwarz T, Luger TA, Beissert S. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol. 2000;165:2374-2381.
36. Geginat J, Sallusto F, Lanzavecchia A, et al. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp Med. 2001;194:1711-1719.
37. Granucci F, Feau, S, Angeli, V, Trottein, F, Ricciardi-Castagnoli, P. Early IL-2 production by mouse dendritic cells is the result of microbial induced priming. J Immunol. 2003;170:5075-5081.
38. Li Y, Li XC, Zheng XX, et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med. 1999;5:1298-1302.
39. Smiley ST, Csizmadia V, Gao W, Turka LA, Hancock WW. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction. Transplantation. 2000;70:415-419.
40. Sho M, Sandner SE, Najafian N, et al. New insights into the interactions between T cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg. 2002;236:667-675.
41. Blaha P, Bigenzahn S, Koporc Z, et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood. 2003;101:2886-2893.
42. Wells AD, Li XC, Li Y, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med. 1999;5:1303-1307.
43. + regulatory T cells. Nat Immunol. 2003;4:330-336.
44. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-1061.
45. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163:5211-5218.
46. Steitz J, Bruck J, Lenz J, Knop J, Tuting T. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res. 2001;61:8643-8646.
47. Liyanage U, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-2761.
48. Woo E, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766-4772.